Long-term data reinforce durable efficacy and safety of POMBILITI + OPFOLDA in late-onset Pompe disease SAN RAFAEL, Calif., Oct. 2, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced new data evaluating the efficacy and safety of POMBILITI® (cipaglucosidase...
Hence then, the article about biomarin announces five year phase 3 data for pombiliti cipaglucosidase alfa atga opfolda miglustat at world muscle society annual congress was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( BioMarin Announces Five-Year Phase 3 Data for POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at World Muscle Society Annual Congress )
Also on site :
- Buckingham, Doolittle & Burroughs, LLC Celebrates Grand Opening of New Downtown Akron Office with Ribbon-Cutting Ceremony
- Meta faces $40 bn data privacy penalty
- Election debate cancelled in Brazil, bomb scare outside Supreme Court